Movember and SAiGENCI partner on landmark database to drive improvements in prostate cancer care
, the leading global men鈥檚 health charity, has partnered with the South Australian immunoGENomics Cancer Institute (SAiGENCI) at the 成人大片, to create a transformative database that will help researchers develop strategies for clinicians to personalise decisions about prostate cancer care.
The database has been named MSTIR - Movember SAiGENCI Transformational Integrated Repository.
Prostate cancer is the second most commonly diagnosed cancer in men, and the fifth leading cause of cancer death among men worldwide, with an estimated 1.4 million new cases and 397,000 deaths each year1.聽 Sadly, that burden is expected to double to 2.9 million cases by 2040, as the population continues to age.聽 Over that same time, deaths are predicted to surge by 85%2, highlighting the very urgent need to make our current treatments more precise and even more effective.
Over the last two decades, many biological and clinical datasets, from prostate cancer clinical trials and research studies around the world, have been collected.聽 But this data is almost always analysed in isolation, never reaching its full potential.
Movember and the 成人大片 recognise the profound insights that could be leveraged by combining and analysing these datasets.聽 That鈥檚 why they're joining forces to develop MSTIR - a world-first, integrated database that will harness the power of innovative technologies like artificial intelligence and machine learning, to analyse the existing data obtained from analyses of tissue samples and clinical data from thousands of men worldwide enrolled in clinical trials.聽 This is one of the most reliable strategies to identify new biomarkers.聽 These insights will inform treatment strategies, ensuring each man gets the right treatment at the right time.聽 It aims to stop aggressive prostate cancer from growing, coming back, or spreading rapidly.
鈥淭his cutting-edge technology represents a monumental leap in prostate cancer research.聽 Allowing us to gather prostate cancer data from around the world and consolidate it in a single repository.聽 By collecting and analysing biomarkers, we can unlock trends, enhance diagnostic pathways and improve the overall management and treatment of the disease.聽 We are proud to see such revolutionary research being conducted here in Australia, and hope that it will play a role in minimising the global burden of prostate cancer in the future,鈥 says Sarah Weller, Movember Global Director of Prostate Cancer.
"MSTIR is a world-wide collaboration bringing together many types of researchers from all around the globe to help unlock a new level of understanding of prostate cancer. This is an exciting and promising opportunity that could deliver more accurate diagnoses, more effective treatments, and improved outcomes for men battling this disease. At the very heart of this unique endeavour is the international team-spirit and collaborative sharing of data which is enabling the repurposing and integrating of existing valuable data."
The 成人大片 has been at the forefront of the fight against cancer for decades. Launching MSTIR in the University's 150th year is very auspicious and we're incredibly excited to be able to add to the many discoveries that have and are emanating from the 成人大片. We're incredibly excited to see what kind of discoveries come out of this. The team at the 成人大片 is honoured to partner with Movember to make this project possible.Professor Christopher Sweeney, Director, SAiGENCI, 成人大片
The database forms part of Movember and the 成人大片鈥檚 joint mission to prevent, and/or slow the spread of prostate cancer, before it becomes a fatal disease.聽 Their goal is to improve the length and quality of life for the 1 in 5 Australian men who face a prostate cancer diagnosis in their lifetime.
Movember鈥檚 partnership with the 成人大片 was the result of a competitive global Request for Proposal (RFP) process.
A beta version of the database is expected to be ready in mid-2025, with plans to scale access in 2026.
1 Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi帽eros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: , accessed [07 JUN 2024].
2 The Lancet: The Lancet Commission on prostate cancer: planning for the surge in cases, published April 4, 2024